Targeting hyperglycaemia with anti-obesity drugs: Time for a paradigm shift?

Drugs

Volumn 73, Issue 15, 2013, Pages 1649-1651

  Krentz, Andrew J ^a   Hompesch, Marcus ^a  

^a Profil Institute for Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIOBESITY AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN; LIPID; LORCASERIN; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; QYSMIA; RIMONABANT; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG;

BODY MASS; CALORIC INTAKE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PRACTICE GUIDELINE; REVIEW; WEIGHT GAIN; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANTI-OBESITY AGENTS; CARBOHYDRATE METABOLISM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPID METABOLISM; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84887239084     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0123-2     Document Type: Review

References (24)

1. Klein S, Sheard NF, Pi-Sunyer X, et al. Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care. 2004;27:2067-73. (Pubitemid 38989258)
2. Taylor R. Type 2 diabetes: etiology and reversibility. Diabetes Care. 2013;36:1047-55.
3. Guidlines for the management of type 2 diabetes. 2012. http://www.idf.org. Accessed 11 July 2013.
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19:327-36.
6. Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
7. Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009;11:361-71.
8. Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care. 2005;28:942-9. (Pubitemid 40434504)
9. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006;368:1660-72. (Pubitemid 46048528)
10. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-52.
11. Astrup AV, Oppert J-M, Peterson CA. Weight loss and improvements in cardiometabolic outcomes with extended-release phentermine/topiramate treatment in overweight/obese subjects with type 2 diabetes. Diabetologia 2012;55(suppl 1):S48.
12. Redman LM, Ravussin E. Lorcaserin for the treatment of obesity. Drugs Today. 2010;46:901-10.
13. Nigro SC, Luon D, Baker WL. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Curr Med Res Opin. 2013;29:839-48.
14. Hoy SM. Lorcaserin: a review of its use in chronic weight management. Drugs. 2013;73(5):463-73.
15. Bai B, Wang Y. The use of lorcaserin in the management of obesity: a critical appraisal. Drug Des Dev Ther. 2010;5:1-7.
16. Gallwitz B. Novel oral anti-obesity agents: new perspectives with lorcaserin? Drugs. 2013;73:393-5.
17. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426-36.
18. Kenkre J, Tan T, Bloom S. Treating the obese diabetic. Expert Rev Clin Pharmacol. 2013;6:171-83.
19. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity. 2009;17:494-503.
20. Chan EW, He Y, Chui CS, Wong AY, Lau WC, Wong IC. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev. 2013;14(5):383-92.
21. Krentz AJ. Rosiglitazone: trials, tribulations and termination. Drugs. 2011;71:123-30.
22. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs: insights from the rosiglitazone experience. N Engl J Med. Epub 2 Sep 2013
23. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15:540-59.
24. Raz I, Riddle MC, Rosenstock J, et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a diabetes care editors' expert forum. Diabetes Care. 2013;36:1779-88.